2. Search Result
Search Result
Isoforms Recommended: CYP11
Results for "

CYP11A1

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

1

Natural
Products

1

Recombinant Proteins

2

Antibodies

6

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156628
    Opevesostat

    MK-5684; ODM-208

    		 Cytochrome P450 Cancer
    Opevesostat (MK-5684; ODM-208) is an orally active and selective CYP11A1 inhibitor. Opevesostat has the potential for the research of metastatic castration-resistant prostate cancer (mCRPC) .
    Opevesostat
  • HY-16276
    Osilodrostat
    4 Publications Verification

    LCI699

    		 Mineralocorticoid Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Osilodrostat (LCI699) is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat inhibits aldosterone and corticosterone synthesis. Osilodrostat has blood pressure lowering ability. Osilodrostat can be used for research of Cushing syndrome (CS) .
    Osilodrostat
  • HY-B0105B
    Levoketoconazole
    1 Publications Verification

    (-)-Ketoconazole; (-)-Ketoconazol; (-)-R 41400

    		 Cytochrome P450 Infection Inflammation/Immunology
    Levoketoconazole ((-)-Ketoconazole) is the 2S,4R enantiomer derived from racemic Ketoconazole (HY-B0105). Levoketoconazole is a potent and orally active cortisol synthesis inhibitor. Levoketoconazole inhibits key steps in cortisol and testosterone synthesis by inhibiting CYP11B1, CYP11A1, and CYP17A1. Levoketoconazole can be used for research on endogenous Cushing’s syndrome .
    Levoketoconazole
  • HY-130705A
    Tachysterol 3

    		VD/VDR Endogenous Metabolite Metabolic Disease
    Tachysterol 3 is a photoproduct of Previtamin D3 (HY-130705) .
    Tachysterol 3
  • HY-16276A
    Osilodrostat phosphate
    4 Publications Verification

    LCI699 phosphate

    		 Mineralocorticoid Receptor Cardiovascular Disease Cancer
    Osilodrostat (LCI699) phosphate is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat phosphate is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat phosphate inhibits aldosterone and corticosterone synthesis. Osilodrostat phosphate has blood pressure lowering ability. Osilodrostat phosphate can be used for research of Cushing syndrome (CS) .
    Osilodrostat phosphate
  • HY-156530
    CYP11A1-IN-1

    		Cytochrome P450 Endocrinology
    CYP11A1-IN-1 (compound 30) is an inhibitor of CYP11A1, with IC50 value of 201-2000 nM. CYP11A1-IN-1 can be used for research in steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer .
    CYP11A1-IN-1
  • HY-103322
    6-Bnz-cAMP sodium salt

    		PKA Potassium Channel Metabolic Disease Cancer
    6-Bnz-cAMP sodium, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K + channel. 6-Bnz-cAMP sodium does not activate the Epac signaling pathway. It inhibits the bTREK-1 K + channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP sodium activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. It can be used in studies related to bone tissue repair and regeneration .
    6-Bnz-cAMP sodium salt
  • HY-W679754
    Pentacosafluorotridecanoic Acid

    PFTrDA

    		 Biochemical Assay Reagents Cytochrome P450 Metabolic Disease
    Pentacosafluorotridecanoic Acid (PFTrDA) is a long-chain perfluoroalkyl carboxylic acid with strong endocrine-disrupting activity. Pentacosafluorotridecanoic Acid exhibits estrogenic effects and disrupts vtg1 transcription as well as sex hormone homeostasis in male Danio rerio. Pentacosafluorotridecanoic Acid disturbs steroidogenesis and HPG axis function in a sex-dependent pattern. Pentacosafluorotridecanoic Acid inhibits CYP17A and CYP11A1 to reduce testosterone and increase E2/T ratio in H295R cells. Pentacosafluorotridecanoic Acid triggers gender-specific immunomodulation after prenatal exposure. Pentacosafluorotridecanoic Acid correlates with lower eczema risk in female infants. Pentacosafluorotridecanoic Acid can be used for the research of endocrine disruption and eczema .
    Pentacosafluorotridecanoic Acid
  • HY-101217
    BI 689648

    		Cytochrome P450 Endocrinology
    BI 689648 is a novel, highly selective aldosterone synthase inhibitor which can inhibit CYP11B1 and CYP11B2 with IC50s of 310 and 2.1 nM, respectively.
    BI 689648
  • HY-RS03434
    CYP11A1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CYP11A1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP11A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CYP11A1 Human Pre-designed siRNA Set A
    CYP11A1 Human Pre-designed siRNA Set A
  • HY-RS23937
    Cyp11a1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cyp11a1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cyp11a1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cyp11a1 Rat Pre-designed siRNA Set A
    Cyp11a1 Rat Pre-designed siRNA Set A
  • HY-RS17479
    Cyp11a1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cyp11a1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cyp11a1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cyp11a1 Mouse Pre-designed siRNA Set A
    Cyp11a1 Mouse Pre-designed siRNA Set A
  • HY-181747
    CYP11A1-IN-3

    		Cytochrome P450 Cancer
    CYP11A1-IN-3 (Compound II-4) is a selective CYP11A1 inhibitor with an IC50 of 26.7 nM. CYP11A1-IN-3 shows selectivity towards CYP1A2, 2C9 and 2D6. CYP11A1-IN-3 can be used for the research of castration-resistant prostate cancer .
    CYP11A1-IN-3
  • HY-179686
    CYP11A1-IN-2

    		Cytochrome P450 Cancer
    CYP11A1-IN-2 (Compound 61) is a selective cholesterol side-chain cleavage enzyme (CYP11A1) inhibitor. CYP11A1-IN-2 can inhibitor steroid biosynthesis and can be used for the research of steroid hormone-dependent cancers, such as prostate cancer .
    CYP11A1-IN-2
  • HY-151140
    CYP11B1-IN-2

    		Cytochrome P450 Others
    CYP11B1-IN-2 (compound 7aa) is an orally active, potent and selective CYP11B1 inhibitor, with IC50 values of 9 nM and 25 nM for human CYP11B1 and rat CYP11B1, respectively. CYP11B1-IN-2 can be used for the research of diseases caused by excessive cortisol .
    CYP11B1-IN-2
  • HY-135281
    CYP11B2-IN-1

    		Cytochrome P450 Cardiovascular Disease
    CYP11B2-IN-1 is a CYP11B2 inhibitor with an IC50 of 2.3 nM. CYP11B2-IN-1 inhibits CYP11B1 with an IC50 of 142 nM .
    CYP11B2-IN-1
  • HY-W679754R
    Pentacosafluorotridecanoic Acid (Standard)

    PFTrDA (Standard)

    		 Reference Standards Biochemical Assay Reagents Cytochrome P450 Metabolic Disease
    Pentacosafluorotridecanoic Acid (Standard) is the analytical standard of Pentacosafluorotridecanoic Acid (PFTrDA) (HY-W679754). This product is intended for research and analytical applications.Pentacosafluorotridecanoic Acid is a long-chain perfluoroalkyl carboxylic acid with strong endocrine-disrupting activity. Pentacosafluorotridecanoic Acid exhibits estrogenic effects and disrupts vtg1 transcription as well as sex hormone homeostasis in male Danio rerio. Pentacosafluorotridecanoic Acid disturbs steroidogenesis and HPG axis function in a sex-dependent pattern. Pentacosafluorotridecanoic Acid inhibits CYP17A and CYP11A1 to reduce testosterone and increase E2/T ratio in H295R cells. Pentacosafluorotridecanoic Acid triggers gender-specific immunomodulation after prenatal exposure. Pentacosafluorotridecanoic Acid correlates with lower eczema risk in female infants. Pentacosafluorotridecanoic Acid can be used for the research of endocrine disruption and eczema .
    Pentacosafluorotridecanoic Acid (Standard)
  • HY-RS03435
    CYP11B1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CYP11B1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP11B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CYP11B1 Human Pre-designed siRNA Set A
    CYP11B1 Human Pre-designed siRNA Set A
  • HY-RS17315
    Cyp11b1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cyp11b1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cyp11b1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cyp11b1 Mouse Pre-designed siRNA Set A
    Cyp11b1 Mouse Pre-designed siRNA Set A
  • HY-163751
    STING-IN-9

    		Mineralocorticoid Receptor Metabolic Disease
    STING-IN-9 (compound 2) is a potent inhibitor of human CYP11B2. STING-IN-9 showed more than 80 times higher selectivity over human CYP11B1 in vitro .
    STING-IN-9
  • HY-176480
    CYP11B2-IN-3

    		Cytochrome P450 Cardiovascular Disease
    CYP11B2-IN-3 (compound 32) is an orally active and selective CYP11B2 inhibitor with IC50 values of 12.92 nM and 2341 nM for CYP11B2 and CYP11B1, respectively. CYP11B2-IN-3 can be used for study of hypertension .
    CYP11B2-IN-3
  • HY-16276R
    Osilodrostat (Standard)

    LCI699 (Standard)

    		 Mineralocorticoid Receptor Reference Standards Cardiovascular Disease Inflammation/Immunology Cancer
    Osilodrostat (Standard) is the analytical standard of Osilodrostat. This product is intended for research and analytical applications. Osilodrostat (LCI699) is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat inhibits aldosterone and corticosterone synthesis. Osilodrostat has blood pressure lowering ability. Osilodrostat can be used for research of Cushing syndrome (CS) .
    Osilodrostat (Standard)
  • HY-122744
    CYP11B1-IN-1

    		Cytochrome P450 Metabolic Disease Cancer
    CYP11B1-IN-1 (Compound 25) is a selective, orally active hCYP11B1 inhibitor, with an IC50 of 2 nM against hCYP11B1 and an IC50 of 1.8 μM against rat CYP11B1. CYP11B1-IN-1 can be used for the research of Cushing's disease .
    CYP11B1-IN-1
  • HY-RS23770
    Cyp11b1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cyp11b1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cyp11b1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cyp11b1 Rat Pre-designed siRNA Set A
    Cyp11b1 Rat Pre-designed siRNA Set A
  • HY-101217R
    BI 689648 (Standard)

    		Cytochrome P450 Reference Standards Endocrinology
    BI 689648 (Standard) is the analytical standard of BI 689648 (HY-101217). This product is intended for research and analytical applications. BI 689648 is a novel, highly selective aldosterone synthase inhibitor which can inhibit CYP11B1 and CYP11B2 with IC50s of 310 and 2.1 nM, respectively.
    BI 689648 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: